Article Figures & Data
Additional Files
Data Supplement
- Supplemental Data -
Supplementary Figure S1. Gefitinib and AZD8931 sensitivity in HNSCC cell lines.
Supplementary Figure S2. Sensitivity of HNSCC cell lines to the MTOR inhibitor, AZD8055, and rapamycin.
Supplementary Figure S3. Synergistic growth inhibition of HNSCC cells with combined AZD8931 or gefitinib and MEK inhibitor, selumetinib.
Supplementary Figure S4. Synergistic growth inhibition of HNSCC cells with combined AZD8931 or gefitinib and MEK inhibitor, trametinib.
Supplementary Figure S5. Effect of combined AZD8931 and trametinib treatment on phospho-ERK and phospho-EGFR levels in JHU011 cells.
Supplementary Figure S6. Lack of HNSCC growth inhibition by the AKT inhibitor, MK2206.
- Supplemental Table 1 -
Supplementary Table 1 - Ranked protein kinases from the essential kinase screen in HNSCC cells.
- Supplemental Table 2 -
Supplementary Table 2 - Ranked protein kinases from the synthetic lethal screen with AZD8931 in HNSCC cells.
- Supplemental Data -